

Research Article

Received on: 29-06-2015

Accepted on: 30-09-2015

Published on: 12-10-2015

Corresponding Author:

Padmini Mishra

Research fellow, Collaborative Research Program, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, India

Email: dradheims@gmail.com



QR Code for Mobile users

Conflict of Interest: None Declared !

Role of Ayurvedic plants in prevention and management of Senile Dementia of Alzheimer's type: A Review

Padmini Mishra^a, Aruna Agrawal^b, Priyanka Purohit^c, G.P. Dubey^d, GP Singh^e

^aResearch fellow, Collaborative Research Program, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, India

^bCoordinator (Advance Center for traditional and Genomic medicine), Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, India

^cScientific Officer, Collaborative Research Program, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, India

^d Distinguish Professor, Coordinator Collaborative Research Program, Institute of Medical Sciences, Banaras Hindu University, India

^e Professor, Adesh University, Bhatinda, Punjab, India

Abstract:

Senile dementia is one of the age associated, irreversible, mental problem characteristic symptoms of various neurodegenerative diseases. It is considered as the most common form of dementia and it is observed that people over the age of 70 years suffers from a significant memory loss. It includes forgetfulness, difficulty in performing routine task, acetylcholine deficiency and inflammation of brain tissue. Although there is no cure for Alzheimer's disease but drugs are designed to delay the progression of disease. Various biomarkers has been well established which diagnose the Alzheimer's disease. Medicinal plants have been used for the development of drugs, almost 100 new products are already in clinical development. This review gathers various medicinal plants and their constituents, have been used in traditional system of medicine for treatment of cognitive impairment. Plants such as *Curcuma longa*, *Bacopa monneri*, *Hippophae rhamnoides*, *Centella asiatica* and *Ginkgo biloba* are used in the prevention and treatment of Alzheimer's disease and various biomarkers are also discussed.

Keywords- Alzheimer's disease, senile dementia, amyloid peptide, antioxidant activity, anti-inflammatory, loss of memory.

Introduction:

Alzheimer's disease (AD) which is considered as one of the most important neuro-degenerative diseases is also characterized by progressive cognitive deterioration along with decline in the activities of routine life leading to neurophysiatric symptoms or abnormal behaviour [1]. The principle cause of dementia is the degenerative condition of neuronal cells known as Alzheimer's disease. When it affects people under 65 years it is termed as pre-senile dementia. The second most common cause of vascular disease of brain is termed as multi-infract dementia. In the past, it was termed as arteriosclerotic dementia. However, AD is the most common type of pre-senile and senile dementia [2]. It is the major cause of dementia in later life and is characterized by severe, progressive problems in moving newly learned information into long term memory [3-4]. It also includes a pattern of forgetfulness, short attention span difficulty in performing routine task, language the problems,

disorientation, poor judgement problem with thinking, misplacing things, depression, irritability, paranoia, hostility and lack of initiative. Various studies suggests that persons with mild cognitive impairment are at increased risk for progressing to AD [5]. The disease result in progressive loss of memory and gradually patients lose the ability to function and to take care of themselves [6-7] because of ageing brain cells become inefficient for glucose intake and mitochondrial energy production. This allows for the buildup of cellular debris, eventually destroying neuronal cells and causing age related cognitive decline. Nutrients that restore energy and their production may therefore, help to prevent or control brain ageing.

Senile dementia

Senile dementia is the mental deterioration (loss of intellectual ability) that is associated with old age. Two major types of senile dementia are identified: those due to generalized "atrophy" (Alzheimer's -type dementia) and those due to vascular problems (mainly, strokes). Senile

dementia is often used when referring to Alzheimer's disease.

In senile dementia there is the loss of neurons in the locus coeruleus. White matter changes in brains from patients with dementia. There is reduction in the level of acetylcholine due to increase in the activity of acetylcholinesterase (AChE). The activity of dopamine (DA), noradrenalin (NA) and 5-hydroxytryptamine (5-HT) system also reduces. The active amines decrease while the end metabolites decrease to lesser extent or normal. The level of active amines reflects the number of neurons, while the levels of end metabolites show the rate of turnover in the system. 3-Methoxy-4-hydroxyphenylglycol (MHPG) increases above normal levels. This indicates an increase in the rate of turnover in the NA system. Monoamine oxidase increases in advanced age, which further increases in patients with AD and SD. This is assumed that enzyme localizes in extra neuronal tissue, and increase reflects gliosis. In brains from patients with AD and SD neuropeptides are studied. Only somatostatin and substance P however, seems to reduce, which indicates selective damage of neuropeptides.

Stages of Alzheimer's diseases

Stage 1- No impairment- memory and cognitive abilities appear normal.

Stage 2- Minimal impairment/normal forgetfulness- memory lapses and changes in thinking are rarely detected by friends, family or medical personnel; about half of all people over 65 begin noticing problem in concentration and word recall.

Stage 3- Early confusional/mild cognitive impairment. While subtle difficulties begin to impact function, the person may consciously or subconsciously try to cover up his or her problems. Difficulty with reverting words, planning, organization, misplacing objects and forgetting recent learning, which can affect life at home and work. Depression and other changes in can also occur. Duration: 2 to 7 years.

Stage 4- Late confusional/mild Alzheimer's. Problems handling finances result from mathematical challenges. Recent events and conversations are increasingly forgotten, although most people in this stage still know themselves and their family. Problems carrying out sequential tasks, including cooking, driving, ordering food at restaurants, and shopping. Often withdraw from social situations, becomes defensive, and deny problems. Accurate diagnosis of Alzheimer's disease is possible at this stage. Lasts roughly 2 years.

Stage 5- Early Dementia / Moderate Alzheimer's disease. Decline is more severe and requires assistance. No longer able to manage independently or recall personal history and contact information. Frequently disoriented regarding

place Stage 5- Early Dementia / Moderate Alzheimer's disease. People in this stage experience a severe decline in numerical abilities and judgment skills, which can leave them vulnerable to scams and at risk from safety issues. Basic daily living tasks like eating and dressing require increased supervision. Duration: an average of 1.5 years.

Stage 6- Middle Dementia / moderately Severe Alzheimer's disease. Total lack of awareness of present events and inability to accurately remember the past. People in this stage progressively lose the ability to take care of daily living activities like dressing, toileting, and eating but are still able to respond to nonverbal stimuli, and communicate pleasure and pain via behavior. Agitation and hallucinations often show up in the late afternoon or evening. Dramatic personality changes such as wandering or suspicion of family members are common. Many can't remember close family members, but know they are familiar. Lasts approximately 2.5 years.

Stage 7- Late or Severe Dementia and Failure to Thrive. In this final stage, speech becomes severely limited, as well as the ability to walk or sit. Total support around the clock is needed for all functions of daily living and care. Duration is impacted by quality of care and average length is 1 to 2.5 years.

At an anatomical level Alzheimer's disease is characterized by gross diffuse atrophy of brain and loss of neurons, neuronal processes and synapses in cerebral cortex and certain sub-cortical regions. This results in gross atrophy of affected regions, including degeneration in temporal lobe, parietal lobe, parts of frontal lobe and cingulate gyros [8]. Level of neurotransmitter such as acetylcholine, serotonin, nor-epinephrine, somatostatin are reduced in neurodegenerative disorder but glutamate levels remain usually elevated [9]. The pathological changes and modification are observed in AD, brain tissue and increased levels of both the Amyloid- β ($A\beta$) peptide, deposited extracellularly in diffuse and neuritic plaques, and hyperphosphorylated tau (p-tau), a microtubule assembly protein that accumulates intracellularly as neurofibrillary tangles (nFts) along with loss of neuron cells and synapses. However, because of the numerous pathogenic factors are associated with progression of AD whereas the synthetic drugs have a low response rate and with limited effect. Frequently, drugs are associated with major side-effects and the chronic toxicity that affect almost every organ system and effect on cognition and behaviour [10]. Recently, the usage of medicinal herbs has supported new alternatives source of anti-Alzheimer's for the treatment of AD and these herbal medicines are potentially beneficial for treating certain neurodegenerative disorder. The use of herbal formulation finds the way of curing AD. Ayurveda declared, more than a few plants of herbal formulation,

the so-called 'Madhya' plants, possess such antioxidant, and anxiolytic properties. In Ayurvedic, numerous medicinal plants have been used to treat neurodegenerative diseases such as AD and modify the progress and symptoms of AD. Recently, some ethnopharmacological techniques has been discovered and used for identifying potential new anti-Alzheimer's drugs from herbal sources and these drugs involve in the improvement of cognitive decline and AD's symptoms [11].

This reviews article is reported in different plants and their active constituents have been used in traditional Ayurvedic medicine for the management of AD.

Prevalence and incidence

In United States more than 4.0 million people over the age of 60 are affected with AD whereas in India its total prevalence is per 1000 people and in future this number is increases four times by 2050. According to World Health Organization (WHO), females (6%) are more affects with AD than male (5%) and its frequency increases to 50% by the age of 80 years [12-13].

Risk factors

The etiological factors of disease ranges from oxidative injures ,autoimmune complexes ,inflammatory factors platelet aggregations, syntheses and degradation of Amyloid proteins ,deficiency neuro-transmitters and cerebro-vascular pathology to neuronal degeneration. In population studies ,higher dietary intake of fat and calories is found to be associated with increased risk for Alzheimer's disease, whereas high intake of fish oil, rich in omega -3 fatty acids ,such as DHA(Docosahexanoic acid) is associated with a decreased risk[14-17]. Amyloid beta is a short peptide, that is an abnormal by product of the transmembrane protein Amyloid precursor protein (APP) whose function is unclear but thought to be involved in neuronal development [18].The pre-senile are component of proteolytic complex involved in APP processing and degradation [19].

On the other hand, plaques which contain misfolded protein in beta amyloidal form in brain produce clinical signs of Alzheimer's disease and plaques together with neurofibrillary tangles are the prominent pathologic signs of the disease. These features can only be discovered as autopsy and help to confirm the clinical diagnosis. Medications can reduce the symptoms of disease, but they cannot change the course of underlying pathology [20]. Therefore, both Amyloid plaques and neurofibrillary tangles are clearly visible by microscopy in Alzheimer's disease's brain.

Nwmba et al (1991)., had reported the apolipoprotein E (Apo E) is found in brain plaques and neurofibrillary tangles [21],is not only characteristic of Alzheimer's

disease ,but is also present in healthy brain. The Apo-E gene is inherited as one of three alleles, e2, and e3 and e4 allele conferring increased risk of developing Alzheimer's disease in older adults [22]. A number of epidemiological studies have demonstrated that the frequency of e4 is markedly higher in AD [23-25] whereas the elevated high -density of lipoprotein cholesterol is associated with significantly decreased risk of dementia, independent of Apo-E status and other potential variables suggesting that cholesterol fractions could be involved in both Alzheimer's disease and vascular dementia. The prevalence of Alzheimer's disease increases with the degree of artherosclerosis. The Rotterdam study has shown that indicators of atherosclerosis of the carotid arteries and presence of atherosclerosis of large vessels of the legs are associated with Alzheimer's disease [26]. A strong interaction between Apo-E ,e4 allele and atherosclerosis was observed suggesting that at least one Apo-E ,i.e. e4 allele and severe atherosclerosis had nearly 20 times increased risk for Alzheimer's disease[26-27].

Recently, some studies have revealed that mutation in pre-senile -1or pre-senile -2 have been documented in some families. Mutation of pre-senile -1 lead to most aggressive form of familial AD [28]. Evidence from rodent studies suggests that the familial AD mutation of presenile-1 results in impaired hippocampus dependent learning which is correlated with adult neurogenesis [29]).Sometimes environmental factors have claimed to increase risk of Alzheimer's including prior head injury, particularly repeated trauma, previous incidents of migraine headaches, exposure to defoliants and low activity adulthood [30-33].

Ageing or oxidative damages in brain, itself cannot be barred, but its senescence can be diminished. It is important to understand that interventions that reduce the risk of developing disease in the first phase but may not alter disease progression after symptoms become apparent. Adults with damaged blood vessels in the brain or atrophy in their temporal lobe are most likely to develop AD. It is known that blood vessel damage in the brain is more likely to occur in patients suffering with high blood pressure, high cholesterol or diabetes. Therefore, prevention of these conditions can lower risk of developing AD as well as heart attack and stroke. Therefore, cause factor of adult AD has not yet been well understood at molecular level. It has been identified as protein misfolding disease due to the accumulation of abnormally folded Amyloid beta protein in the brains of AD patients [34].

Some studies have declared that senile dementia Alzheimer's type was found associated with the decrease in the cerebral cortical levels of several proteins and neurotransmitters, particularly, acetylcholine its synthetic

enzyme, choline acetyl transferase (ChAT) and nicotinic cholinergic receptors. Reduction of acetylcholine may be particularly related to degeneration of cholinergic neurons in the nucleus basal is of Meynert and also many areas of cortex as well as reduction in the non-adrenaline levels in brain stem. Early identification of AD provides an opportunity to enhance quality of life and long term care.

Biomarkers

A biomarker is independently evaluated as an indicator of normal biological, pathogenic processes and pharmacological responses to a therapeutic intervention and can differentiate healthy person from diseased one. Therefore, epidemiological research discovering various biomarkers for identification of AD and biomarkers are also involved in the diagnosis of mild to moderate AD. Internationally, these biomarkers have been well-established to diagnose AD in cerebro spinal fluid with ELISAs: β -Amyloid, total tau and phospho-tau-181 [35-36].

Treatment, Management and herbal medicine

The administration of medications and monitoring of their effects in the elderly peoples compromise one of the most important and complex aspects of health care. A broad range of modern non-tropic and physic tropic agents are being used to manage the age related cognitive impairment and associated functional disorders. But the long term interventions of such agents have their own limitations due to adverse effect of various biological systems [37]. Age related cognitive decline occur gradually but sudden cognitive decline is not a part of normal ageing. When people develop an illness such as AD mental deterioration usually happens quickly. In contrast, cognitive performance in elderly normally remains stable over many years, with only slight decline in short-term memory and reaction times (38-40).By transporting fatty acid into mitochondria, the amino acid acetyl-L carnitine with the antioxidant lipoic acid helps reverse mitochondrial breakdown, oxidative damage and memory loss [41-42]. Several clinical trials suggest the acetyl-L carnitine and phosphotidylserine delays the onset of age related cognitive decline and improve overall cognitive function in the elderly subjects [43-44].

The studies have suggested that between antioxidant intake and age related cognitive decline. Higher blood level of vitamin-c, beta carotene [45] and vitamin -e supplementations accelerated learning and prevent memory deficits associated with oxidative stress [46-48]. Similarly high intake of mono-unsaturated fatty acids and caffeine has been associated with protection against age related cognitive decline [49-50]. Intellectual stimulation, regular physical exercise, social interaction, diet with fruits and vegetables and low in saturated fat, vitamin B, folic

acid, omega-3, fatty acids, Docosahexaenoic acid, vitamin -E, all reduce Alzheimer's risk [51-52].

Acetyl cholinesterase inhibitor is important to enhance the activity of cholinergic neurons. AChE inhibitors reduce the rate at which acetylcholine is broken down and hence increase the concentration of AChE in the brain. Acetyl cholinesterase -inhibitors seemed to modestly moderate symptoms but do not alter the course of the underlying process [53].

Currently available medications offer relatively small symptomatic benefit for some patients but do not slow disease progression. Tacrine, donepezil, galantamine and revastigmine drugs generally used for the treatment of Alzheimer's disease, all drugs have doubtful clinical utility, and many side effects [54-55]. The statin has been found to reduce the incidence of Alzheimer's disease and Parkinson's disease by almost 50 percent as reported by researchers from Boston University School of Medicine. Some currently approved drugs such as statins and thiazolidinediones have also been used for the treatment of and prevention of Alzheimer's disease [56].

Plant origin medicines are gaining popularity and are being investigated for a number of disorders, including neurodegenerative disorders like AD. A number of scientific researches have been carried out on medicinal herbs and investigated that possess anti-Alzheimer's activity. Numerous reports have been declared the plants possess anti-inflammatory and antioxidant activities that may be used in the treatment of AD because anti-inflammatory and antioxidant activities of plants reduced the inflammation and aging of neuronal cells of the brain in AD. Medicinal Plants contain natural COX-2 inhibitors that inhibit acetyl choline

Esterase (AChE) and enhances the cholinergic system in the brain may be useful in treating AD.

In Ayurveda, some herbs like Shankhpushpi, Amalaki, Gugguli, Guduchi, Yashtimadhuk, Padma (Nelumbo nucifera), Vacha, Convolvulus pluricaulis, Pancha-Tikta-Ghruta, Musta Arjun, Amalaki, Ashwagandha, Galo Satva, Kutaj etc, are splendid herbs for decline brain neurodegeneration caused by Alzheimer's and boost the brain's ability to function, and therefore, make available steadiness. We have highlighted some of the important plants for their anti-Alzheimer's properties, in our laboratory and elsewhere during the last few years (Table-1).

Table 1 List of medicinal plants used for treatment of senile dementia

Plant	Family	Reference
<i>Bacopa monniera</i>	Scrophulariaceae	59
<i>Curcuma longa</i>	Zingiberaceae	57,11,58
<i>Ginkgo biloba</i>	Ginkgoaceae	59,11
<i>Salvia officinalis</i>	Lamiaceae	60
<i>Rosmarinus officinalis</i>	Lamiaceae	61
<i>Matricaria recutita</i>	Asteraceae	62
<i>Melissa officinalis</i>	Lamiaceae	63
<i>Glycyrrhiza glabra</i>	Fabaceae	64
<i>Galanthus nivalis L.</i>	Amaryllidaceae	65-66
<i>Huperzia serrata</i>	Lycopodiaceae	67
<i>Commiphora whighitti</i>	Burseraceae	68-69
<i>Lipidium Meyenii Walp</i>	Brassicaceae	70
<i>Panax Ginseng</i>	Araliaceae	71,11
<i>Acorus calamus</i>	Araceae	72
<i>Angelica archangelica</i>	Umbelliferae	73
<i>Tinospora cordifolia</i>	Menispermaceae	74
<i>Magnolia officinalis</i>	Magnoliaceae	74
<i>Collinsonia Canadensis</i>	Lamiaceae	75
<i>Bertholettia excelsa</i>	Lecythidaceae	76
<i>Urtica dioica</i>	Clusiaceae	77,11
<i>Withania somnifera</i>	Solanaceae	78

Bacopa Monneri* (Brahmi)*Taxonomical classification**

Kingdom: plantae
 Division: angiospermae
 Class: dicotyledonae
 Order: lamiales
 Family: scrophulariaceae
 Genus: bacopa
 Species: monniera



In ayurvedic system, brahmi (*Bacopa monnieri*) act as a nerve tonic, diuretic, and cardiogenic and used in the treatment of epilepsy, insomnia, asthma, and rheumatism. It contains some bioactive molecules such as saponins and triterpenoid bacosaponins that include bacosides III to V, bacosides A and B, and bacosaponins A, B, C and glycosides include bacosides III to V, bacosides A and B, and bacosaponins A, B, C and glycosides include the jujubogenin bisdesmosides bacosaponins D, E, F, alkaloids, plant sterols, betulinic acid, polyphenols, and sulphahydril compounds bacosides A and B, and bacosaponins A, B, C and glycosides include the jujubogenin bisdesmosides bacosaponins D, E, F, alkaloids, plant sterols, betulinic acid, polyphenols, and sulphahydril compounds that have antioxidant activity [57]. It inhibited cholinergic degeneration, reversed the depletion of acetylcholine, reduction in choline acetyltransferase activity, and decrease in muscarinic cholinergic receptor binding in the frontal cortex and hippocampus and protected neurons from beta-amyloid-induced cell death by suppressing cellular acetylcholinesterase activity. Thus, BM improved memory and cognitive function and treat the AD [79].

Mechanism of action

Bacopa has been described as one of the most popular medicinal drugs (nootropic agent). Several studies have revealed that this medicinal herb is advocated as a nervine and mental tonic and may be used for the treatment of neurological and mental disorders [80-83]. In another recent study conducted in an animal model, *Bacopa* has been shown to decrease whole brain AChE activity which reflects that *Bacopa* might prove to be a useful memory restorative agent in the treatment of Alzheimer's and dementia [84-85]. A clinical study on human subjects has demonstrated the potential of *Bacopa monniera* in the treatment of Neuritis.

Centella asiatica* (Mandookparni/ Brahmi)*Taxonomical classification**

Kingdom: Plantae
 Division: Angiospermae
 Class: Dicotyledonae
 Order: Umbelliferae
 Family: Apiaceae
 Genus: *Centella*
 Species: *asiatica*



C. Asiatica is a slender perennial creeper which grows throughout the tropical regions in the world. The leaf, known locally as Gotu Kola, has been used in AM for revitalizing and strengthening nervous function and memory. For example, an Ayurvedic formulation composed of 4 herbs, including *C. asiatica* is used as a restorative and for the prevention of dementia [86]. In TCM, it is also used to combat physical and mental exhaustion [87-88]. An alcoholic extract of the plant possessed tranquilising and potentially cholinomimetic activities *in vivo*, which may be due to the presence of the triterpenoid brahminoside [88]. Aqueous extract of the whole plant enhanced cognitive function in rats, which was associated with the *in vivo* antioxidant activity of the extract [94]. An aqueous extract modulated dopaminergic, serotonergic and adrenergic systems *in vivo* and improved learning and memory [88].

Mechanism of action

Centella asiatica has been demonstrated to possess neuroprotective property. [89] The studies have revealed that *Centella asiatica* has been demonstrated to possess neuroprotective property. [89] The studies have revealed that *Centella asiatica* has ability to prevent cognitive deficits that occur following treatment with Streptozotocin and to protect cholinergic neurons from the toxic effects of aluminium indicating its role in reducing the Alzheimer's disease neuropathy. [89-90] Recent study conducted on transgenic animal model to evaluate the efficacy of *Centella asiatica* extract (CaE) in the management of A.D. It has shown that CaE can impact the amyloid cascade altering amyloid β pathology in the brains of PSAPP (presenilin 'Swedish' amyloid response that has been implicated in the neurodegenerative changes occurring in Alzheimer's disease.

Nardostachys jatamansi (Jatamansi)

Taxonomical classification

Kingdom: Plantae
 (Unranked): Angiosperms
 (Unranked): Eudicots
 (Unranked): Asterids
 Order: Dipsacales
 Family: Caprifoliaceae
 Genus: *Nardostachys*
 Species: *N. jatamansi*



In the Ayurvedic system of medicine, the rhizomes and roots of the *Jatamansi* contain a variety of sesquiterpenes, coumarins and valerian including terpenoids, spirojatamol, nardostachysin, jatamols A and B, and calarenol [91]. Its extract has antioxidant property and significantly improved learning and memory and restoring memory in older individuals as well as in patients with age-associated dementia [92].

Mechanism of action

It is thought to be via MAPK inhibition [93] or preventing pancreatic stellate cell activation (noted with *jatamansi* *in vitro* [94]) which is a common pancreatitis treatment target. [95] An increase in heme-oxygenase 1 (HO-1) has also been noted. [96]

Protective effects have been noted on the beta-cells of the pancreas, where oral ingestion of *Jatamansi* prior to streptozotocin injections significantly protected from diabetes. [97] This was replicated *in vitro* in response to cytokine damage. Its mechanism is thought to be preventing NF- κ B downstream of pro-diabetic stressors. [98-99]

Hippophae rhamnoides (sea-buckthorn)

Taxonomical classification

Kingdom: Plantae
 Subkingdom: Tracheobionta
 Division: Magnoliophyta
 Class: Magnoliopsida
 Subclass: Rosidae
 Order: Rhamnales
 Family: Elaeagnaceae
 Genus: *Hippophae*
 Species: *rhamnoides*



Leaves of *Hippophae rhamnoides* are equally important in medicinal properties, as they carry some unique flavonoides [100]. *Hippophae rhamnoides* is also rich in flavonoid (vitamin P) and contains appreciable amounts of water 2-dimethylaminoethanol (DMAE) may increase the levels of brain neurotransmitter acetylcholine. In one preliminary trial, people with senile dementia were given DMAE supplement. It showed positive behavior changes (. Emerging evidence suggest a possible benefit of DHAE supplementation in people with Alzheimer's disease. Most studies have found people with Alzheimer's disease have lower blood DHEA levels than the normal control [101].

In a preliminary study, people who used antioxidant supplement (vitamin C or vitamin E) had a lower risk of Alzheimer's disease compared with people who did not take antioxidant. Large amount of supplement of vitamin E may slow the progression of Alzheimer's disease . Fruit of *Hippophae rhamnoides* is quite rich in vitamin C (300-600 mg/100 gm), which is 4-100 times higher than many fruits and vegetables [103-104]. *Hippophae rhamnoides* is a potent anti-oxidant. In experimental and clinical studies, the anti-oxidant effect of *Hippophae rhamnoides* is proven. The fruit, seed, and leaves of *Hippophae rhamnoides* contain an impressive array of antioxidant compound. The leaves are an equally rich source of important antioxidants including beta carotene. Vitamin E, flavonoids, catechins , elagic acid, ferulic acid [103].

Mechanism of action

Antimicrobial and antitumoral effects ,the phenolic compounds of *Hippophae rhamnoides* have the inhibitory effects against Gram-negative bacteria.[104] 70% *Hippophae rhamnoides* branches extract has proven activity against TPA induced tumor . This activity is because of three phenolic compounds such as catechin ,galloocatechin and epigallocatechin.[10] Antiulcerogenic effect Hexane extract of *Hippophae rhamnoides* has activity against indometacin; stress and ethanol induced gastric ulcer.[104] Liver diseases according to Zhao et al *Hippophae rhamnoides* could be used to protect liver from damage by calcium tetrachloride . Branches extract has proven activity against TPA induced tumor.[104] Liver diseases According tetrachloride. Combining *Hippophae rhamnoides* juice with antivirus can shorten the normalization time of serum ALT. [105]

***Ginkgo biloba*(Ginkgo)**

Kingdom: Plantae
Division: Ginkgophyta
Class: Ginkgoopsida
Order: Ginkgoales
Family: Ginkgoaceae
Genus: Ginkgo
Species: biloba



Ginkgo biloba is a dioecious perennial tree and is indigenous to East Asia and is used in TCM for improvement of memory loss and release hippocampus in vivo. For improvement of cognitive function, administration of plants extract AD to non AD patients in various randomized, double blind, placebo controlled and multi centre trials. [106]. *Ginkgo biloba* is a plant extract containing several compounds that may have positive effects on cells within brain and body. *Ginkgo biloba* is thought to have both anti inflammatory and anti oxidant properties to protect cell membrane and to regulate neurotransmitters function. *Ginkgo* has been used for centuries in traditional Chinese medicine and currently is being used in Europe to alleviate cognitive symptoms associated with number of neurological conditions.

Mechanism of action

The mechanism of action of ginkgo is believed to be produced by functions as a neuroprotective agent ,an antioxidant ,a free radical scavenger , a membrane stabilizer ,and an inhibitor of platelet –activating factor via the terpene ginkgolide B.[106,107] Other pharmacologic effects include the following : endothelium relaxation mediated by inhibition of 3',5'-cyclic GMP(guanosine monophosphate) phosphodiesterase[108,109]; inhibition of age –related loss of muscarinergic cholinceptors and alpha-adrenoreceptors ;and stimulation of choline uptake in hippocampus .[109,110] *Ginkgo* extract also have been shown to inhibit beta-amyloid deposition.[111]

***Curcuma longa* (Turmeric)**

Taxonomical classification

Kingdom: plantae
Division: magnoliophyta
Class: liliopsida
Subclass: zingiberidae
Order : zingiberales
Family: zingiberaceae
Genus: curcuma
Species: c.longa



Curcuma longa is a rhizomatous herbaceous perennial plant of the ginger family, Zingiberaceae and derived from the rhizome and root. In Asia, it is used as a spice and coloring agent and in traditional medicine. Its active constituents are curcuminoids, including curcumin and it is the principal curcuminoid, responsible for the yellow colour of the turmeric root. *Curcuma longa* possess anti-inflammatory, anti allergy, antiseptic, antioxidant and antibacterial activity including detoxify the liver, balance cholesterol levels stimulate digestion, and boost immunity and due to their non-steroidal anti-inflammatory property of turmeric is associated with a reduced risk of AD[112-113].

Mechanism of action

Curcumin appears to: increase the secretion of bile, promote the flow of bile to the intestine, it protect the liver (hepatoprotective effect) and support liver function, raise the level of glutathione in the liver ; stimulate the activity of glutathione S-transferase in the liver ; promote the detoxification of toxic substances ;inhibit blood platelet aggregation ; posses antibiotic properties ;lower the cholesterol level; possess antioxidative properties ;have a catabolic and metabolic effect on fat absorption ;have inflammation –inhibiting properties ; have a fungicidal effect on ,amongst others ,candida albicans.

Conclusion

The pharmaceutical company is facing serious challenges to find a lead molecule in neurodegenerative diseases and is becoming extremely expensive, riskier, and critically inefficient. With regard to diet and treatment option Indian system of medicine has gained increasing recognition in recent years. Early development of medicinal plant supplements required only epidemiologic information without an understanding mode of action . The natural product industry has come a long way from when it was considered unnecessary to test medicinal plants and their chemical component prior to use and to the introduction of good manufacturing practice guidelines for the industry. It might be worth pointing out that, while medicinal plants and their products has been prescribed for centuries for neurodegenerative diseases. It

provides strong support for herbal therapy for AD. It is hoped that strong knowledge base of medicinal plant and natural product will improve the ease with which medicinal plant products and formulations can be used in drug discovery programme and development process, thereby providing new functional leads for AD and other age associated neurodegenerative diseases.

References

1. McKhann G, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984; 34:939-944. [Pub Med: 6610841]
2. Evans DA, Funkenstein, HH & Albert MS. Prevalence of Alzheimer's disease in a community population of older persons. *Journal of the American Medical Association*, 262.1989; 2551-2556, .
3. Ferri CP, Prince M, Brayne C, et al. "Global prevalence of Dementia: a Delphi consensus study". *Lancet*. 2005; 366 (9503):2112-7.
4. Gao S, Hendrie HC, Hall KS, et al. The relationships between age, sex and the incidence of dementia and Alzheimer's disease. A meta - analysis. *Arch Gen Psychiatry*; 55:809-815, 1998.
5. Bushke H, Kulansky G, Katz M et al. Screening for dementia with the Memory impairment Screen. *Neurology*. 1999; 52:231-238.
6. Albert MS, Drachman DA. Alzheimer's disease: what is it ,how many people have it, and why do we need to know? *Neurology*. 2000; 55:166-168.
7. Peterson RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol*. 1999; 56:303-8.
8. Hebert LE, Scherr PA, Beckett LA, et al. Age -specific incidence of Alzheimer's disease in a community population. *JAMA*. 1995; 273:1354-1359 .
9. Wenk GL. Neuropathologic changes in Alzheimer's disease. *J Clin Psychiatry* 64 Suppl. 2003; 9:7-10.
10. Baskys, Receptor found that could lead to better treatments for stroke, Alzheimer's disease. *UCI Medical Centre*. Retrieved on. 2006; 11-04-.
11. Mao, Q. Q., Huang, Z., Zhong, X. M., Feng, C. R., Pan, A. J., Li, Z. Y., Che, C. T. (2010). Effects of SYJN, a Chinese herbal formula, on chronic unpredictable stress-induced changes in behavior and brain BDNF in rats. *Journal of Ethno pharmacology*. 2010; 128(2), 336-341. doi:10.1016/j.jep.
12. Anil Kumar Singhal, Vijay Naithani, Om Prakash Bangar. Medicinal plants with a potential to treat Alzheimer and associated symptoms. 2012; 2: 2; 84-91.
13. Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. *Drugs Aging*. 1999 Nov; 15(5):365-75.
14. Alzheimer's Association. 2010 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2010; 6:158-194.
15. Grant WB. Dietary links to Alzheimer's disease. *Alzheimer Dis Rev*. 1997 2:42-55.
16. Smith MA, Petot GJ, Perry G. Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. *Alzheimer Dis Rev*. 1997 2: 58-9.
17. Kalmijian S, Feskens EJM, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants and cognitive function in very old man. *Am J Epidemiol*. 1997; 145:33-41.
18. Miyanaga K, Yanoemura K, Takagi T, et al. Clinical effects of DHA in demented patients. *J Clin Ther Med*. 1995 ;11:881-901.
19. Kerr ML, Small DH. Cytoplasmic domain of the A β -amyloid protein precursor of Alzheimer's disease: Function ,regulation of proteolysis

- ,and implications for drug development .J Neurosci Res 80(2) .2005;151-9.
20. Cai D ,Neter WJ Zhong M,Lin Y,Du G ,Froham M ,Foster DA ,Sisodia SS, Xu H ,Gorelick FS ,Greengard P. Presenilin-1 uses phospholipase D1 as a negative regulator of beta –amyloid formation .Proc Natl Acad Sci USA .2006;103(6):1941-6.
21. Ferri CP, Prince M, Brayne C C,et al.”Global prevalence of dementia: a Delphi consensus study “.Lancet .2006;366(9503):2112-7.
22. Namba Y,Tomonaga M,Kawasaki H,Otomo E ,Ikeda K . Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt –Jakob disease .Brain Res1991; 541:163-6 .
23. Corder EH ,SaundersAM ,Strittmatter WJ,Schmechel DE,Gaskell PC,Small GW,Roses AD ,Haines JL, Pericak –ance MA.Gene dose of apolipoprotein E type 4 allele and risk of Alzheimer’s disease in late onset families .Science . 1993;261:921-932.
24. Gearing, M., Mori, H and Mirra, S.S.”A beta –peptide length and apolipoprotein E genotype in Alzheimer’s disease “. Annuals of Neurology.1996; 39,395-399.
- 25.Ramassamy ,C., Averrill ,D ., Beffert ,U ., Bastianetto ,S., Theroux ,L.,Lussiercacan ,S . Cohn ,JS ., Christen,Y., Davignon,J ., Quirion , R.and Poirier ,J ,”Oxiditive damage and protection by antioxidants in the frontal cortex of Alzheimer’s disease is related to apolipoprotein E genotype “. Free Radical Biology and Medicine.1999; 27,544-553 .
- 26.Bonarek,M.,Barberger-Gatesu,P.,Letenneur,L.Deschamps,V.,Iron,A., Dubroca,B.and Dartigues, J.F.”Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cros.sectional analysis from the PAQUID study” Neuroepidemiology .2000;19,141-148.
27. Hofman,A.,Ott ,A., Breteler,M,M,B.,Bots,M.L.,Slooter,A., J.C.,Van HarsKamp,F.van Duijn ,C.M.,van Broeskhoven,C.and Grobbee, D.E.:Atherosclerosis, apolipoprotein E and the prevalence of dementia and Alzheimer’s disease the Rotterdam Study”,Lancet.1997; 349,151-154.
28. Slooter ,A.J.C ., Cruts, M ., Ott ,A .,Bots ,M.L., Wittteman ,J.C.M., Hofman,A., van Broeckhoven ,C., Breteler ,M.M.B .and van Duijn ,C.M.”The effect of apo E on dementia is not through atherosclerosis: the Rotterdam Study “.Neurology .1999;53, 1593 -1595.
29. Vetrivel KS,Zhang YW, Xu H ,Thinakaran G .”Pathological and physicochemical functions of presenilins.”Mol Neurodegener .2006;12:1-4.
- 30.Wang R,Dineley K,Sweatt J,Zheng H .”Presenilin 1FamiliarAlzheimer’s disease mutation leads to defective associative learning and impaired adult neurogenesis.”Neuroscience.2004;126 (2):305-12.
31. Munoz DG, Feldman H.”Causes of Alzheimer’s disease.”CMAJ 162 .2000 ;(1):65 -72.
32. Tyas SL, Manfreda J, Strain LA, Montgomery PR.”Risk factors for Alzheimer’s disease: a population based, longitudinal study in Manitoba, Canada.”.Int J Epidemiol 30(3):590-7,2001.
33. Jellinger KA.”Head injury and dementia.”Curr Opin Neurol 17(6):719-23, 2006.
- 34.Guskiewicz KM, Marshall SW, Balies J, McCrea M, Cantu RC, Randolph C, Jordan BD.’Association between recurrent concussion and late –life cognitive impairment in retired professional football players.”.Neurosurgery .2006;57 (4):719-26.
- 35.Hashimoto M, Rockenstein E ,Crews L ,Masliah E .Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases ,Neuromolecular Med.2003; 4 (1-2):21-36.
- 36.Cooper ,J K,Mungas ,D ,Verma ,M,Weiler ,PG.Psychotic symptoms in Alzheimer’s .Int J Ger .Psychiatry .1991;6,721 -726 .
- 37.Christian Humpel. Identifying and validating biomarkers for Alzheimer’s disease. Trends Biotechnol. 2011 Jan; 29(1): 26–32
- 38.Eidsderfer C, Friddel RO.(eds).Cognitive and Emotional Disturbance in Elderly .Chicago,Year Book Medical1978.
- 39.Ferris SH,Kluger A.Commentary on age –associated memory impairment ,age-related cognitive decline and mild cognitive impairment Ageing Neuropsychol Cogn .1996;3:148-53.
- 40.Nussbaum, PD,ed. Handbook of Neuropsychology and ageing .New York :Plenum 1997.
- 41.Rubin EH, Storandt M, Miller JP ,et al .A prospective study of cognitive function and onset of dementia in cognitively healthy elders .Arch Neurol .1998;55 (3):395-401.
- 42.Aureli T ,Di Cocoo ME ,Capuani G et al .Effect of long –term feeding with acetyl –L-carnitine on the age –related changes in rat brain lipid composition : a study by 31 P NMR spectroscopy .Neurochem Res. 2000 25 (3):395-9.
- 43.Hagen TM, Liu J,Lykesfeldt J ,et al .Feed –ing acetyl –L – Carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress .Proc Natl Acad Sci USA .2002;99(4):1870-5.
- 44.Maggioni M ,Picotti GB ,Bondiolotti GP ,ei al .Effects of phosphatidylserine therapy in geriatric patients with depressive disorders .Acta Psychiatr Scand 1990;81 (3):265-70.
- 45.Salvioli G ,Neri M .L-acetylcarnitine treatment of mental decline in the elderly Drugs Exp Clin Res .1994;20 (4):169-76.
- 46.Miyamoto M, Murphy TH, Schnaar RL,Coyle JT . Antioxidants protect against glutamate induced cytotoxicity in a neuronal cell line.J Pharmacol Exp Ther. 1989.
- 47.Joseph JA,Shukitt –Hale B ,Denisova NA,et al .Long –term dietary strawberry ,spinach ,or Vitamin E supplementation retards the onset of age –related neuronal signal –transduction and cognitive behavioural deficits .J Neurosci.1998;18(19) :8047-55.
- 48.Masaki KH ,Losonczy KG ,Izmirlian G,et al .Association of Vitamin E and C supplement use with cognitive function and dementia in elderly men .Neurology.2000; 54:1265-72.
- 49.Fukui K .Omoi NO ,Hayasaka t ,et a .Cognitive impairment of rats caused byoxidative stress and ageing ,and its prevention by Vitamin E.Ann NY Acad Sci .2002;959:275 -84.
- 50.Solfrizzi V, Panza F et al .High monounsaturated fatty acids in –take protects against age –related cognitivedecline.Neurology .1999;52 (8):1563-9 .
- 51.Jarvis MJ. Dose caffeine enhances absolute levels of cognitive performance? Psychopharmacology (Berl).1993; 1109(1-2):45-52.
- 52.Verghese J ,Lipton R,Katz M Hall C, Derby C, Kuslansky G,Ambrose A ,Sliwinski M, Buschke H,” Leisure activities and the risk of dementia in the elderly .” N Engl JMed .2003;348(25):2508-16.
- 53.Larson E Wang L Bowen J ,McCormick W ,Teri L ,Crane P,Kukll W “Exercise is associated with reduced risk for in incident dementia .among persons 65 years age and older,” Ann Intern Med .2006;144(2):73-81.
- 54.Eisai Inc,”Aricept and Aricept ODT Product Insert”,March 2005.
- 55.Courtney C ,Farrell D ,Gray R ,Hills R ,Lynch L,Sellwood E ,Edwards S,Haryman W ,Raftery J ,Crome P ,Lendon C ,Shaw H ,Bentam P.”Long –term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double blind trial.”Lancet .2004;363(9427)2105 -15.
- 56.Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H, van den Bussche H.”Cholinesterase inhibitors for patients with Alzheimer’s disease: systemic review of randomized clinical trials.”BMJ.2005; 331(7512):321-7.
- 57.Landreth G.”PPAR gamma agonists as new therapeutic agents for treatment of Alzheimer’s disease.”Exp Neurol .1999;(2):24 .
58. Goswami S, Saoji A, Kumar N, Thawani V, Tiwari M, Thawani M. Effect of Bacopa monnieri on Cognitive functions in Alzheimer’s disease patients. Int J Collab Res Intern Med Public Health 2011; 3:285-93.

59. Duke JA. Rosemary, the herb of remembrance for Alzheimer's disease. *Altern Complement Ther* Dec 2007;287-90.
60. Prakash JC, Sirsi M. Comparative study of the effects of brahmi (*Bacopa monnieri*) and chlorpromazine on motor learning in rats. *J Sci. Ind. Res.* 1962; 21: 93-97.
61. Ji YA, Suna K, Sung EJ and Tae YH. Food Sci Biotechnol. Effect of licorice (*Glycyrrhiza uralensis fisch*) on Amyloid- β -induced neurotoxicity in PC12 cells. 1999;1391-5.
62. Bilge S, Ilkay O. Discovery of drug candidates from some Turkish plants and conservation of biodiversity. *Pure Appl. Chem.* 2005; 77:53-64.
63. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, et al., and Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. *J Pharmacol Exp Ther* 1996; 277:728-38.
64. Ilkay O, Gürdal O and Bilge S. An update on plant-originated treatment for Alzheimer's disease. *Ethnomedicine: A Source of Complementary Therapeutics* 2010;245-65.
65. Available from: <http://www.holistictherapypractice.com>. [Last accessed on 2011 Jul 25]
66. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. *Behav Neurosci* 1998; 112:1199-208.
67. Rubio J, Qiong W, Liu X, Jiang Z, Dang H, Chen SL, et al., Aqueous Extract of Black Maca (*Lepidium meyenii*) on Memory Impairment Induced by Ovariectomy in Mice. *Evid Based Complement Alternat Med* 2008.
68. Fu LM, Li JT. A systematic review of single Chinese herbs for Alzheimer's disease treatment. *Evid Based Complement Alternate Med* 2009.
69. Park CH, Kim SH, Choi W, Lee YJ, Kim JS, Kang SS, et al., Novel anticholinesterase and anti-amnesic activities of dehydroevodiamine, a constituent of *Evodia ruraecarpa*. *Planta Med* 1996; 62:405-9.
70. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. *Behav Neurosci* 1998; 112:1199-208.
71. Available from: <http://herbal-ayurveda-remedy.com>. [Last accessed on 2011 Jun 24].
72. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. *Behav Neurosci* 1998; 112:1199-208.31.
73. Available from: <http://www.herbalcureandtreatments.com>. [Last accessed on 2011 Jun 25].
74. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. *Behav Neurosci* 1998; 112:1199-208.
75. Available from: <http://www.livestrong.com>. [Last accessed on 2011 Jun 23].
76. Keyvan D, Damien DH J, Heikki V, Raimo H. Plants as Potential Sources for Drug Development against Alzheimer's disease. *Int J Biomed Pharm Sci* 2007; 1:83-104.
77. Keyvan D, Damien DH J, Heikki V, Raimo H. Plants as Potential Sources for Drug Development against Alzheimer's disease. *Int J Biomed Pharm Sci* 2007; 1:83-104.
78. Kumar S, Christopher JS, Edward JO. Kinetics of acetylcholinesterase inhibition by an aqueous extract of *withania somnifera* roots. *International Journal of Pharmaceutical Sciences and Research* 2011; 2: 1188-92.
79. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity of *Bacopa monniera* in rat frontal cortex, striatum and hippocampus. *Phytother Res.* 2000;14:174-179. doi: 10.1002/(SICI)1099-1573(200005)14:3<174::AID-PTR624>3.0.CO;2-O. [PubMed] [Cross Ref]
80. Morgan A, Stevens J. Does *Bacopa monnieri* improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. *J Altern Complement Med.* 2010 Jul; 16(7):753-759.
81. Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic *Bacopa monniera* Linn. (*Brahmi*). *Indian Journal of Pharmacology* 1997; 29(5): 5359-5365.
82. Singh HK, Dhawan BN. Effect of *Bacopa monniera* Linn. (*brahmi*) extract on avoidance responses in rat. *J Ethnopharmacol.* 1982; 5 (2):205-214.
83. Gupta M, Singh V, Abbas SS, Bhalla M, Singh N. A Preliminary Clinical Study on the effects of Organic Bami (*Centella asiatica* Linn.) in cases of Paralysis, Loss of Memory and Epilepsy. National Seminar on Eco-friendly Herbs of Ayurveda in the Health-care of Mankind: A strategy for Scientific Evaluation and Uniform Standardization, 2004, pp.
84. Joshi H, Parle M. *Brahmi rasayana* improves learning and memory in mice. *Evid Based Complement Alternat Med.* 2006; 3(1):79-85.
85. Manyam BV. Dementia in Ayurveda. *Journal of Alternative Complementary Medicine* 1999;5:81-88. <http://dx.doi.org/10.1089/acm.1999.5.8153>.
86. Duke JA, Ayensu ES. Medicinal plants of China Algonac (MI) 1985; 2 Suppl 2:483-485.54.
87. Brinkhaus B, Lindner M, Schuppan D, Hahn EG. Chemical, pharmacological and clinical profile of the East Asian medicinal plant *Centella asiatica*. *Phytomedicine* 2000; 7: 427-448. [http://dx.doi.org/10.1016/S0944-7113\(00\)80065-355](http://dx.doi.org/10.1016/S0944-7113(00)80065-355).
88. Sakina MR, Dandiya PC. A psycho neuropharmacological profile of *Centella asiatica* extract. *Fitoterapia* 1990; 61:291-296.56.
89. Kumar MHV, Gupta YK. Effect of different extracts of *Centella asiatica* on cognition and markers of oxidative stress in rats. *Journal of Ethnopharmacology* 2002;79:253-260. [http://dx.doi.org/10.1016/S03788741\(01\)00394](http://dx.doi.org/10.1016/S03788741(01)00394).
90. Zhou Y. Study on the effect of hippophae seed oil against gastric ulcer, Institute of medical plants resource development, the Chinese academy of medical sciences, 1998. mor Promoters Phenolics And Triterpenoid From Hippophae Rhamnoides. *Fitoterapia*. 2009; 80 (3): 164-7. Bae GS, et al Effect of biologically active fraction of *Nardostachys jatamansi* on cerulein-induced acute pancreatitis. *World J Gastroenterol.* (2012)
91. Bae GS, et al *Nardostachys jatamansi* inhibits severe acute pancreatitis via mitogen-activated protein kinases. *Exp Ther Med.* (2012)
92. Bae GS, et al The inhibitory effects of *Nardostachys jatamansi* on alcoholic chronic pancreatitis. *BMB Rep.* (2012)
93. Haber PS, et al Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. *Am J Pathol.* (1999)
94. Malik J, Karan M, Vasisht K. Nootropic, anxiolytic and CNS-depressant studies on different plant sources of shankhpushpi. *Pharm Biol.* 2011; 49:1234-1242. doi: 10.3109/13880209.2011.584539.
95. Sethiya NK, Nahata A, Mishra SH, Dixit VK. An update on Shankhpushpi, a cognition-boosting Ayurvedic medicine. *Zhong Xi Yi Jie He Xue Bao.* 2009; 7:1001-1022. doi: 10.3736/jcim20091101.
96. Bagchi A, Oshima Y, Hikino H. Neolignans and Lignans of *Nardostachys jatamansi* Roots 1. *Planta Med.* 1991; 57:96-97.
97. Joshi H, Parle M. *Nardostachys jatamansi* improves learning and memory in mice. *J Med Food.* 2006; 9:113-118. doi: 10.1089/jmf.2006.9.113.
98. Guseva AR and Nestuk MN. K medtadike opredelenia flavonolovykh veshstva v rasteniakh. *J. Biokhem.* 18 (4):480-485, 1995.

100. Hillen T, Lun A, Reischies FM, et al. DHEA-S plasma levels and incidence of Alzheimer's disease. *Biol Psychiatry*; 47:161-3, 2000.
101. Rosch, D., Bergmann, M., Knorr, D. and Kroh, L.W. Structure-antioxidant efficiency relationships of phenolic compounds and their contribution to the antioxidant activity of sea buckthorn juice. *Journal of Agricultural and Food Chemistry* 51, 4233-9, 2003.
102. Eccleston, C., Baoru, Y., Tahvonen, R., Kallio, H., Rambach, G.H. and Minihane, A.M. Effects of an antioxidant rich juice (sea buckthorn) on risk factors for coronary heart disease in humans. *Journal of Nutritional Biochemistry* 13, 346-54, 2002.
103. Gao, X., Ohlander, M., Jeppsson, N., Bjork, L. and Trajkovski V. Changes in antioxidant effects and their relationship to phytonutrients in fruits of sea buckthorn (*Hippophae rhamnoides rhamnoides L*) during maturation. *Journal of Agricultural and food chemistry* 48, 1485-90, 2000.
104. Guliyev VB, Gul M, Yildirim A. *Hippophae rhamnoides L*: chromatographic methods to determine chemical composition, use in traditional medicine. *Journal of Alternative Complementary Medicine* 1999;5:8188. <http://dx.doi.org/10.1089/acm.1999.5.8153>
105. Ken Y, Susumu K, Kenji K, Kumiko G. Anti-Tumor Promoters Phenolics And Triterpenoid From *Hippophae Rhamnoides*. *Fitoterapia*. 2009; 80 (3):
106. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. *Phytomedicine* 1997;4:3-13. [http://dx.doi.org/10.1016/S09447113\(97\)800. to Traditional Medicine, 2008, pp. 77](http://dx.doi.org/10.1016/S09447113(97)800. to Traditional Medicine, 2008, pp. 77).
107. Oberpichler H, Sauer D, Rossberg C, Mennel HD, Krieglstein J. PAF antagonist ginkgolide B reduces postischemic neuronal damage in rat brain hippocampus. *J Cereb Blood Flow Metab.* 1990; 10:133-5.
108. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. In: Lawson LD, Bauer R. *Phytomedicines of Europe: chemistry and biological activity*. Washington, D.C.: American Chemical Society, 1998:210-20.
109. World Health Organization. WHO monographs on selected medicinal plants. Vol. 1, Ch. 16. *Folium Ginkgo*. Geneva: World Health Organization, 1999:154-67.
110. De Feudis FV. Ginkgo biloba extract (EGb 761): pharmacological activities and clinical applications. Amsterdam: Elsevier, 1991:1187-9. De Feudis FV. Ginkgo biloba extract (EGb 761): from chemistry to the clinic. Wiesbaden: Ullstein Medical, 1998.
111. Watanabe CM, Wolfram S, Ader P, Rimbach G, Packer L, Maquire JJ, et al. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. *Proc Natl Acad Sci U S A.* 2001; 98:6577.
112. Elias EJ, Anil S, Ahmad S, Daud A. Colon targeted curcumin delivery using guar gum. *Nat Prod Commun* 2010; 5:915-8.
113. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. *Neurobiol Aging.* 1995; 16:523-530. doi: 10.1016/0197-4580(95)00049-K.

Cite this article as:

Padmini Mishra, Aruna Agrawal, Priyanka Purohit, G.P. Dubey, GP Singh. Role of Ayurvedic plants in prevention and management of Senile Dementia of Alzheimer's type: A Review. *Asian Journal of Complementary and Alternative Medicine*, 03(10), 2015, 01-11.